Raglan Capital was founded in 2007 by former directors of Merrion Capital bringing with them significant expertise in analysing, managing and deal making across a broad range of sectors.

Since 2007, Raglan Capital has grown steadily, and the team now includes experienced professionals from a variety of backgrounds. The Raglan Capital team’s breadth of experience has enabled us to successfully complete a variety of proprietary projects primarily within the Life Sciences and Natural Resources sectors. Our focus in to create one new company in-house each year with the intention of rapidly listing them on the London and Dublin Stock Exchanges within two years post inception.

In 2016, Raglan established Amryt Pharma Plc which is now listed on both the London and Dublin Stock Exchanges. Amryt has a market capitalisation in excess of £50m and is now an established European orphan drug company. The company already has rapidly growing monthly sales revenues while at the same time managing a pipeline of drugs in development including its potential blockbuster EB orphan drug, which is now in its final FDA phase three trials. Following on from the success Amryt Pharma, Raglan established a second orphan focused company in mid-2017 called Open Orphan. Open Orphan is a European & Middle East Focused Orphan Drug, Rare Disease and Specialty Pharma Platform. Open Orphan is led by an experienced Board and management team with expertise in orphan drug regulatory approval, market access and reimbursement, commercialisation and launch optimisation. Open Orphan is due to IPO on both the London and Dublin Stock Exchange in early 2019.

Within Natural Resources, Raglan carry in-depth knowledge and experience having completed a variety of proprietary Oil & Gas projects over the years. T5 Oil & Gas, which is another in-house Raglan creation, is due to complete its IPO before mid-2018. Prior to that, Raglan established Fastnet Oil & Gas plc which floated on the London and Dublin stock exchanges raising over $50m.